Related references
Note: Only part of the references are listed.Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer
Min-Hee Ryu et al.
EUROPEAN JOURNAL OF CANCER (2015)
Vascular Endothelial Growth Factor A Inhibition in Gastric Cancer
Do Joong Park et al.
GASTRIC CANCER (2015)
HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison
T. Koopman et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells
Xiaodi Ding et al.
ANTI-CANCER DRUGS (2014)
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer
Luigi Di Lauro et al.
GASTRIC CANCER (2014)
Impact of Informative Censoring on the Kaplan-Meier Estimate of Progression-Free Survival in Phase II Clinical Trials
Federico Campigotto et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial
Bruno Coudert et al.
LANCET ONCOLOGY (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Subacute reversible toxic encephalopathy related to treatment with capecitabine: A case report with literature review and discussion of pathophysiology
E. Lyros et al.
NEUROTOXICOLOGY (2014)
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Krishnansu S. Tewari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
D. W. Miles et al.
BRITISH JOURNAL OF CANCER (2013)
Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab-refractory breast cancer model
Yuliang Sun et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
Luca Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade
Rohit Singh et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2013)
Reversible posterior leukoencephalopathy syndrome and trastuzumab
Hiroyasu Kaneda et al.
INVESTIGATIONAL NEW DRUGS (2012)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
HER2 testing in gastric cancer: a practical approach
Josef Rueschoff et al.
MODERN PATHOLOGY (2012)
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis
Ling Peng et al.
MOLECULAR BIOLOGY REPORTS (2012)
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study
Jean-Yves Pierga et al.
LANCET ONCOLOGY (2012)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Docetaxel plus Oxaliplatin in Combination with Capecitabine as First-Line Treatment for Advanced Gastric Cancer
K. Amarantidis et al.
ONCOLOGY (2011)
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
M. Reck et al.
ANNALS OF ONCOLOGY (2010)
Comparison of Gastric Cancer Survival Following R0 Resection in the United States and Korea Using an Internationally Validated Nomogram
Vivian E. Strong et al.
ANNALS OF SURGERY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing
Josef Rueschoff et al.
VIRCHOWS ARCHIV (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients
GE Konecny et al.
CLINICAL CANCER RESEARCH (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
MD Pegram et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Share Paper
